Pharmetheus AB, a leading name in the biopharmaceutical industry, is headquartered in Sweden (SE) and operates extensively across Europe and North America. Founded in 2012, the company has established itself as a pioneer in pharmacometrics, offering innovative solutions in model-informed drug development and regulatory submissions. Pharmetheus provides a unique blend of services, including population pharmacokinetics, pharmacodynamics, and quantitative systems pharmacology, which set them apart in the competitive landscape. Their commitment to advancing drug development processes has garnered recognition, positioning them as a trusted partner for pharmaceutical companies aiming to optimise their clinical trials and improve patient outcomes. With a focus on scientific excellence and collaboration, Pharmetheus continues to achieve significant milestones in the realm of drug development.
How does Pharmetheus Ab's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Pharmetheus Ab's score of 14 is lower than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmetheus Ab, headquartered in Sweden (SE), currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Pharmetheus Ab may not have established formal commitments to reduce carbon emissions or may be in the early stages of developing such initiatives. In the context of the industry, many companies are increasingly adopting science-based targets and sustainability practices to mitigate climate impact. However, without specific emissions data or commitments, it is unclear how Pharmetheus Ab aligns with these industry standards. As the company progresses, it may consider setting measurable targets to enhance its environmental responsibility and transparency.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Pharmetheus Ab has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
